| Addressing BBB heterogeneity: a new paradigm for drug delivery to brain tumors JI Griffith, S Rathi, W Zhang, W Zhang, LR Drewes, JN Sarkaria, ... Pharmaceutics 12 (12), 1205, 2020 | 36 | 2020 |
| Combination of sunitinib and PD-L1 blockade enhances anticancer efficacy of TLR7/8 agonist-based nanovaccine H Kim, V Khanna, TA Kucaba, W Zhang, DM Ferguson, TS Griffith, ... Molecular pharmaceutics 16 (3), 1200-1210, 2019 | 34 | 2019 |
| Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer V Khanna, S Kalscheuer, A Kirtane, W Zhang, J Panyam Future drug discovery 1 (1), FDD8, 2019 | 33 | 2019 |
| TLR7/8 agonist-loaded nanoparticles augment NK cell-mediated antibody-based cancer immunotherapy H Kim, V Khanna, TA Kucaba, W Zhang, D Sehgal, DM Ferguson, ... Molecular pharmaceutics 17 (6), 2109-2124, 2020 | 30 | 2020 |
| The influence of the blood–brain barrier in the treatment of brain tumours S Rathi, JI Griffith, W Zhang, W Zhang, JH Oh, S Talele, JN Sarkaria, ... Journal of Internal Medicine 292 (1), 3-30, 2022 | 29 | 2022 |
| Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC) V Khanna, H Kim, W Zhang, P Larson, M Shah, TS Griffith, D Ferguson, ... Scientific reports 11 (1), 3346, 2021 | 20 | 2021 |
| Lisdexamfetamine pharmacokinetic comparison between patients who underwent Roux-en-Y gastric bypass and nonsurgical controls KJ Steffen, AS Mohammad, JL Roerig, JE Mitchell, C Nelson, M Orcutt, ... Obesity Surgery 31, 4289-4294, 2021 | 6 | 2021 |
| Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma W Zhang, RA Vaubel, JH Oh, AC Mladek, S Talele, W Zhang, KL Waller, ... Molecular cancer therapeutics 23 (1), 47-55, 2024 | 1 | 2024 |
| Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors W Zhang, JH Oh, W Zhang, S Rathi, JD Larson, RJ Wechsler-Reya, ... Journal of Pharmacology and Experimental Therapeutics 387 (3), 315-327, 2023 | 1 | 2023 |
| Pharmacokinetics of Panobinostat: Interspecies Difference in Metabolic Stability W Zhang, JH Oh, W Zhang, CC Aldrich, RW Sirianni, WF Elmquist Journal of Pharmacology and Experimental Therapeutics 389 (1), 96-105, 2024 | | 2024 |
| How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors W Zhang, JH Oh, W Zhang, S Rathi, J Le, S Talele, JN Sarkaria, ... Pharmaceutical research 40 (11), 2731-2746, 2023 | | 2023 |
| EMBR-28. CNS DISTRIBUTIONAL KINETICS OF PANOBINOSTAT IN THE MOUSE W Zhang, A Mohammad, R Sirianni, W Elmquist Neuro-Oncology 23 (Supplement_1), i12-i12, 2021 | | 2021 |
